title: A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases.
abstract: We retrospectively analyzed 52 adult patients with hemophagocytic syndrome (HPS). The underlying diseases were heterogeneous, including malignant lymphoma (lymphoma-associated hemophagocytic syndrome [LAHS]) in 26 patients, systemic lupus erythematosus in 3 patients, viral infections in 7 patients, and bacteria] or fungal infections in 6 patients. More than 83% of patients received prednisolone as an initial treatment. Multiple-agent chemotherapies (cyclophosphamide, doxorubicin, and vincristine) were administered to 96% of LAHS patients after a histopathological diagnosis of lymphoma. HPSs were controllable and remissions were achieved except for those patients with LAHS, fulminant Epstein-Barr virus-associated HPS, and an immunosuppressive state. Twenty-one (81%) of the LAHS patients had uncontrollable HPS and died of multiple organ failure and disseminated intravascular coagulation. The median survival time of LAHS patients was 83 days. In contrast, 3 (12%) of the other HPS patients died of multiple organ failure within 44 days.The clinical manifestations and the laboratory findings of LAHS and the other HPSs were too variable to establish the prognosis based only on the findings at the onset of HPS. The prognostic factors of adult HPS were found to be the underlying diseases, notably malignant lymphoma and infections, accompanied by the immunosuppressive state.
authors.affiliation: Third Department of Internal Medicine, Akita University School of Medicine, Japan. naoto@doc.med.akita-u.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Takahashi
authors.forename: A
authors.initials: A
authors.lastname: Chubachi
authors.forename: M
authors.initials: M
authors.lastname: Kume
authors.forename: Y
authors.initials: Y
authors.lastname: Hatano
authors.forename: A
authors.initials: A
authors.lastname: Komatsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Kawabata
authors.forename: N
authors.initials: N
authors.lastname: Yanagiya
authors.forename: Y
authors.initials: Y
authors.lastname: Ichikawa
authors.forename: A B
authors.initials: AB
authors.lastname: Miura
authors.forename: I
authors.initials: I
authors.lastname: Miura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality; D006801:Humans; D007239:Infections / Q000150:complications / Q000401:mortality; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000401:mortality; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate